Bladder Urothelial Carcinoma

About
Mappings

OncoTree: Bladder Urothelial Carcinoma (oncotree:BLCA)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) PD-L1 (CPS) >= 10 Bladder Urothelial Carcinoma Pembrolizumab
Sensitivity (+) PD-L1 >= 1% Bladder Urothelial Carcinoma Nivolumab
Sensitivity (+) PD-L1 >= 5% Bladder Urothelial Carcinoma Atezolizumab
Sensitivity (+) FGFR3 p.R248C Bladder Urothelial Carcinoma Erdafitinib
Sensitivity (+) FGFR3 p.S249C Bladder Urothelial Carcinoma Erdafitinib
Sensitivity (+) FGFR3 p.G370C Bladder Urothelial Carcinoma Erdafitinib
Sensitivity (+) FGFR3 p.Y373C Bladder Urothelial Carcinoma Erdafitinib
Sensitivity (+) FGFR3::TACC3 Bladder Urothelial Carcinoma Erdafitinib
Sensitivity (+) FGFR2::BICC1 Bladder Urothelial Carcinoma Erdafitinib
Sensitivity (+) FGFR2::CASP7 Bladder Urothelial Carcinoma Erdafitinib
Sensitivity (+) FGFR3::BAIAP2L1 Bladder Urothelial Carcinoma Erdafitinib
Sensitivity (+) FGFR3 p.R248C Bladder Urothelial Carcinoma Erdafitinib
Sensitivity (+) FGFR3 p.S249C Bladder Urothelial Carcinoma Erdafitinib
Sensitivity (+) FGFR3 p.G370C Bladder Urothelial Carcinoma Erdafitinib
Sensitivity (+) FGFR3 p.Y373C Bladder Urothelial Carcinoma Erdafitinib
Sensitivity (+) FGFR3::TACC3 Bladder Urothelial Carcinoma Erdafitinib